ArticleActa biomaterialia2020
Controlled release of soy isoflavones from multifunctional 3D printed bone tissue engineering scaffolds.
Article in Acta biomaterialia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 68 citations in OpenAlex.
- Osseointegration Effects of 3D-Printed Porous Titanium-Tantalum Scaffolds with Different Tantalum Contents.ACS omega · 2025Article
- Graded Hydroxyapatite Triply Periodic Minimal Surface Structures for Bone Tissue Engineering Applications.Advanced healthcare materials · 2025Article
- Novel Nanomaterials for Developing Bone Scaffolds and Tissue Regeneration.Nanomaterials (Basel, Switzerland) · 2025Review
- Gingerol-zinc complex loaded 3D-printed calcium phosphate for controlled release application.Drug delivery and translational research · 2025Article
- Vitamin D3 Release from MgO Doped 3D Printed TCP Scaffolds for Bone Regeneration.ACS biomaterials science & engineering · 2024Article
- 3D Printed SiOJournal of medicinal chemistry · 2024Article
- Curcumin and Vitamin C dual release from Hydroxyapatite coated Ti6Al4V discs enhancesMaterials chemistry and physics · 2024Article
- Natural medicine delivery from 3D printed bone substitutes.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Advances in biomaterials for oral-maxillofacial bone regeneration: spotlight on periodontal and alveolar bone strategies.Regenerative biomaterials · 2024Review
- Article
- Article
- Review on Additives in Hydrogels for 3D Bioprinting of Regenerative Medicine: From Mechanism to Methodology.Pharmaceutics · 2023Review
- Phytochemical Compounds Involved in the Bone Regeneration Process and Their Innovative Administration: A Systematic Review.Plants (Basel, Switzerland) · 2023Review
- Human cells with osteogenic potential in bone tissue research.Biomedical engineering online · 2023Review
- 3D printing of conch-like scaffolds for guiding cell migration and directional bone growth.Bioactive materials · 2023Article
- Customized Additive Manufacturing in Bone Scaffolds-The Gateway to Precise Bone Defect Treatment.Research (Washington, D.C.) · 2023Review
- Allicin-Loaded Hydroxyapatite: Enhanced Release, Cytocompatibility, and Antibacterial Properties for Bone Tissue Engineering Applications.JOM (Warrendale, Pa. : 1989) · 2022Article
- Research Progress of Natural Small-Molecule Compounds Related to Tumor Differentiation.Molecules (Basel, Switzerland) · 2022Review
- Effects of Vitamin A (Retinol) Release from Calcium Phosphate Matrices and Porous 3D Printed Scaffolds on Bone Cell Proliferation and Maturation.ACS applied bio materials · 2022Article
- Opportunities and challenges of three-dimensional printing technology in pharmaceutical formulation development.Acta pharmaceutica Sinica. B · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Recent challenges in post-surgical bone tumor management have elucidated the need for a multifunctional scaffold, which can be used for residual tumor-cell suppression, defect repair, and simultaneous bone regeneration. In this perspective, 3D printing allows to create a wide variety of patient-specific implant with complex porous architecture and compatible mechanical strength to that of cancellous bone. Here, a multifunctional bone graft substitute is designed by incorporating the three primary soy isoflavones: genistein, daidzein, and glycitein onto a 3D printed (3DP) tricalcium phosphate (TCP) scaffolds with designed pores, endowing them with in vitro chemopreventive, bone-cell proliferating and immune-modulatory potential. The interconnected porosity and biodegradability of 3DP TCP ceramics have allowed controlled release kinetics of genistein, daidzein and glycitein in acidic and physiological buffer medium for 16 days, which is fitted with Korsmeyer-Peppas model. Presence of genistein, a well-known natural biomolecule shows a 90% reduction in vitro osteosarcoma (MG-63) cell viability and proliferation after 11 days. Meanwhile, daidzein, the other primary isoflavone, promotes in vitro cellular attachment and enhances viability and proliferation of human fetal osteoblast cell (hFOB). Furthermore, controlled release of genistein, daidzein, and glycitein from 3DP TCP scaffold demonstrates improved hFOB cell proliferation, viability, and differentiation in a dynamic flow-perfusion bioreactor, which is utilized to better simulate the clinical microenvironment. Finally, in vivo H&E staining confirms controlled co-delivery of genistein-daidzein-glycitein from 3DP scaffold carefully modulated neutrophil recruitment to the surgery site after 24 h of implantation in a rat distal femur model. These results advance our understanding towards multipronged therapeutic approaches utilizing synthetic bone graft substitutes as a drug delivery vehicle, and more importantly, demonstrate the feasibility of localized tumor cell suppression and bone cell proliferation for post-surgical defect repair application. STATEMENT OF SIGNIFICANCE: Designed multimodal porosity of 3D printed TCP scaffold allows a controlled and sustained release of soy isoflavones, genistein, daidzein and glycitein in both physiological and acidic pH. Presence of genistein shows 90% reduction in vitro bone cancer cell viability and proliferation. Meanwhile, controlled release of genistein, daidzein, and glycitein from 3DP TCP scaffolds demonstrate improved osteoblast cell proliferation, viability, and differentiation in static and dynamic flow-perfusion bioreactor. Furthermore, H&E staining at 24 h post-surgical specimens from rat distal femur model shows neutrophil recruitment at the surgery site is significantly decreased, suggesting the anti-inflammatory property of soy isoflavones. This work provides deeper understanding on the design of a multifunctional 3D printed patient-specific scaffold with enhanced in vitro chemopreventive, osteogenic and in vivo anti-inflammatory ability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.